Document is current

Any future updates will be listed below

Fixed-dose inotuzumab ozogamicin (INO) combined with Vincristine and Prednisone (VP) regimen as induction therapy for newly diagnosed B-cell acute lymphocytic leukemia (B-ALL): a multi-center, open-label, single-arm, prospective clinical study

Crossref DOI link: https://doi.org/10.1038/s41408-026-01589-6

Published Online: 2026-07-28

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark